Picropodophyllin

TargetMol
Product Code: TAR-T6943
Supplier: TargetMol
CodeSizePrice
TAR-T6943-5mg5mg£117.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6943-1mL1 mL * 10 mM (in DMSO)£121.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6943-10mg10mg£135.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6943-25mg25mg£213.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6943-50mg50mg£338.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6943-100mg100mg£523.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6943-500mg500mg£1,018.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃

Images

1 / 1

Further Information

Bioactivity:
Picropodophyllin (PPP) is a specific IGF-1R inhibitor (IC50: 1 nM). Picropodophyllin specifically inhibits the activity and downregulates the cellular expression of IGF1R without interfering with activities of other growth factor receptors, such as receptors for insulin, epidermal growth factor, platelet-derived growth factor, fibroblast growth factor and mast/stem cell growth factor (KIT).
CAS:
477-47-4
Formula:
C22H22O8
Molecular Weight:
414.41
Pathway:
Apoptosis; Tyrosine Kinase/Adaptors
Purity:
0.9941
SMILES:
COc1cc(cc(OC)c1OC)[C@H]1[C@H]2[C@H](COC2=O)[C@@H](O)c2cc3OCOc3cc12
Target:
Apoptosis; IGF-1R

References

Tomizawa M, et al. Oncol Lett. 2014, 8(5), 2023-2026. Girnita A, et al. Cancer Res. 2004, 64(1), 236-242. Wu, Qi, et al. IGF1 receptor inhibition amplifies the effects of cancer drugs by autophagy and immune-dependent mechanisms. Journal for Immunotherapy of Cancer. 9.6 (2021): e002722 Menu E, et al. Blood. 2006, 107(2), 655-660. Bieghs L, et al. Oncotarget. 2014, 5(22), 11193-11208.